Beneficial effects of flavonoids on cardiovascular diseases by influencing NLRP3 inflammasome

被引:0
|
作者
Hai-yan Fang
Xiao-ni Zhao
Meng Zhang
Yao-yao Ma
Jin-ling Huang
Peng Zhou
机构
[1] Anhui University of Chinese Medicine,School of Integrated Chinese and Western Medicine
[2] Anhui Academy of Chinese Medicine,Institute of Integrated Chinese and Western Medicine
[3] Anhui Province Key Laboratory of Chinese Medicinal Formula,undefined
来源
Inflammopharmacology | 2023年 / 31卷
关键词
Cardiovascular diseases; NLRP3 inflammasome; Flavonoids; Molecular docking;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular diseases (CVDs) are a leading cause of global mortality and have a high incidence rate worldwide. The function of inflammasomes in CVDs has received a lot of attention recently, and the nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome may be a new target for the prevention and treatment of CVDs. Flavonoids, which are found in food and plant extracts, inhibited inflammation in CVDs by regulating the NLRP3 inflammasome. CB-Dock was used to investigate whether 34 flavonoids from natural products acted on NLRP3 inflammasome. In brief, the PDB format of NLRP3 was selected as a protein file, and 34 flavonoids in SDF format were selected as the ligand file, and then input to CB-Dock for molecular docking. The docking results showed that epigallocatechin-3-gallate (EGCG), amentoflavone, baicalin, scutellarin, vitexin, silibinin, and puerarin had good binding affinities to NLRP3, which could be used as NLRP3 inhibitors, and aid in the discovery of lead compounds for the design and development of CVDs.
引用
收藏
页码:1715 / 1729
页数:14
相关论文
共 50 条
  • [31] NLRP3 inflammasome in cancer and metabolic diseases
    Sharma, Bhesh Raj
    Kanneganti, Thirumala-Devi
    NATURE IMMUNOLOGY, 2021, 22 (05) : 550 - 559
  • [32] Targeting the NLRP3 inflammasome in inflammatory diseases
    Mangan, Matthew S. J.
    Olhava, Edward J.
    Roush, William R.
    Seidel, H. Martin
    Glick, Gary D.
    Latz, Eicke
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (08) : 588 - 606
  • [33] Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases
    Hua, Fang
    Shi, Lingli
    Zhou, Peng
    INFLAMMOPHARMACOLOGY, 2022, 30 (01) : 137 - 147
  • [34] Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases
    Fang Hua
    Lingli Shi
    Peng Zhou
    Inflammopharmacology, 2022, 30 : 137 - 147
  • [35] Effects of phosphorylation on the NLRP3 inflammasome
    Sandall, Christina F.
    MacDonald, Justin A.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 : 43 - 57
  • [36] Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases
    Wang, Hao-yu
    Lin, Xi
    Huang, Guan-gen
    Zhou, Rong
    Lei, Shu-yue
    Ren, Jing
    Zhang, Kai-rong
    Feng, Chun-lan
    Wu, Yan-wei
    Tang, Wei
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (08) : 1687 - 1700
  • [37] Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases
    Hao-yu Wang
    Xi Lin
    Guan-gen Huang
    Rong Zhou
    Shu-yue Lei
    Jing Ren
    Kai-rong Zhang
    Chun-lan Feng
    Yan-wei Wu
    Wei Tang
    Acta Pharmacologica Sinica, 2023, 44 : 1687 - 1700
  • [38] NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases
    Wang, Yucheng
    Liu, Xiaoxiao
    Shi, Hui
    Yu, Yong
    Yu, Ying
    Li, Minghui
    Chen, Ruizhen
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 91 - 106
  • [39] Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis
    Pinar, Anita A.
    Scott, Tara E.
    Huuskes, Brooke M.
    Caceres, Felipe E. Tapia
    Kemp-Harper, Barbara K.
    Samuel, Chrishan S.
    PHARMACOLOGY & THERAPEUTICS, 2020, 209
  • [40] Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases
    Matthew S. J. Mangan
    Edward J. Olhava
    William R. Roush
    H. Martin Seidel
    Gary D. Glick
    Eicke Latz
    Nature Reviews Drug Discovery, 2018, 17 (9) : 688 - 688